Recently, Trinomab has introduced new shareholders including Bayland Capital, Huajin Avenue (Huajin Securities), CSTC, Xingyuan Capital and Fresscon Capital, while the existing shareholder CMS continued to increase the volume of holdings. This transaction involves nearly 200 millions of RMB, which lays a solid financial foundation for the company.
Trinomab is an innovative biotechnology enterprise and mainly engages in R&D of innovative fully native human mAbs as theapeutic drugs. One of leading products, Trinomab TNM002 injection (anti-tetanus toxin monoclonal antibody), has entered phase III clicical trials with the enrollment of more than 600 subjects being completed in April. NDA of TNM002 is expected to be filled sometime within this year. TNM001 injection (anti-RSV long-acting monoclonal antibody) is also in the clicical development phases, has currently been in Phase I/IIb clinical trials and will soon enter the confirmatory phase II/III clinical trials this fall. IND of TNM009 injection (anti-NGF monoclonal antibody as a pain killer) has recently been approved for clinical trials in China by the National Medical Products Administration (NMPA) in April. Phase I trial of TNM009 will roll out in coming months. To estiblish the capacity for its drug production, Trinomab has already built about 23,000㎡ GMP antibody production facility in the Zhuhai International Health Harbor, which can meet the needs for pre-clinical and clinical- development as well as the commercial production of antibody products.
Mr. Zheng Weihong, CEO and President of Trinomab, said: “Trinomab has launched preparations for IPO process, and joining of new shareholders including Bayland Capital and Huajin Securities will further enhance the company's capital reserves, enhance the ability for commercialization of our products after public listing, and promote the international strategic expansion of Trinomab to better serve patients in need globally”.
About Bayland Capital
Since its establishment in 2019, Bayland Capital has been focusing on equity investment in the field of biomedicine, relying on the industrial background of Pharmaron (Stock Code: 300759.SZ/3759.HK). With a unique industrial perspective, Bayland Capital Team makes use of its rich experience in industry, scientific research, management and capital market to invest globally, focusing on the world's leading biomedical R & D services and technological innovation platforms, biotechnology companies, medical device companies, etc. Bayland Capital is committed to becoming the link and reliable long-term partner of life science, health industry and capital.
About Huajin Avenue (Huajin Securities)
Huajin Securities, as a core member of Zhuhai Huafa Group's financial industry cluster, is the vice chairman unit of Shanghai Securities Association and a fully licensed securities firm with a registered capital of 3.45 billion RMB. In July 2019, the company set up a wholly-owned subsidiary, Huajin Avenue Investment Co., Ltd., to carry out specialized equity investment. In recent years, the company has garnered many industry honors, such as "Securities Company With The Most Growing Value Of The Year" and "The Outstanding Securities Firm Of The Year", and its market position has been steadily improved. There are nearly 20 branches and more than 30 brokerage outlets throughout the country. The company serves the overall strategic situation of the country with high quality and all-round services, support the development of the real economy and promotes the growth of residents' wealth.
About CMS
CMS (867.HK) is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability. The Group has successfully deployed 30 the FIC and BIC innovative products. Meanwhile, on the basis of maintaining our core competitiveness in the fields of cardio-cerebrovascular and gastroenterology, CMS develops in depth and breadth in the specialty therapeutic fields of dermatology and ophthalmology, constantly adding new developmental power to the Group’s steady growth. At the same time, the Group has entered the Southeast Asian market to expand business territory, creating the second growth curve.
About CSTC
Guangdong China Science and Tech Innovation Venture Capital Management Co. Ltd. (Hereinafter referred to as "CSTC") settled in Guangzhou in July 2009 as the initiator and manager of Zhongke Baiyun Equity Investment Fund. CSTC as the first large-scale equity investment fund in Guangdong Province, under the guidance and support of the Guangdong Provincial Committee and the provincial government. CSTC focusing on the investment layout of new energy, new materials and advanced manufacturing, digital economy, life and health science, with a total of 47 IPOs.
About Xingyuan Asset Management
Founded in 2015, Beijing Fuhai Xingyuan Asset Management Co., Ltd. (Hereinafter referred to as "Xingyuan Asset Management") is a professional private equity fund management company providing asset management and wealth appreciation services for institutions and high net worth individuals, focusing on new energy, big health and TMT. Following the concept of value investment, the company is committed to becoming a leading asset management company in the industry, bringing long-term and stable investment returns to investors.
About Fresscon Capital
Zhejiang Fresscon Capital Co., Ltd. was jointly established by Zhejiang Shinkansen Media Investment Co., Ltd., Baida Group and other institutions and the management team. The core staff of the company are experts who have been engaged in equity investment for many years, and the professional composition of the team members covers investment management, financial accounting, law, financial securities, biomedicine and digital economy.
